Lundbeck partners with OpenAI for enterprise AI deployment

Global neuroscience-focused pharmaceutical company H. Lundbeck A/S has entered into a strategic collaboration with OpenAI to deploy enterprise-grade AI tools across its operations. The agreement enables Lundbeck to harness open-artificial intelligence platforms to support its mission of transforming brain health research and therapy development.

Under the collaboration Lundbeck will leverage OpenAI’s ChatGPT Enterprise platform to empower teams from discovery of molecules to delivery of treatments. The company expects the AI-driven tools to enhance decision-making, accelerate innovation and streamline processes across research and development and global operations.

With brain- and central nervous system-related disorders remaining difficult to treat, the integration of advanced AI capabilities marks a bold step for Lundbeck which has previously embraced high-performance computing and AI collaborations in drug discovery. The new partnership with OpenAI signals a broader ambition to apply generative and analytic AI across its value chain and amplify productivity while staying aligned with its neuroscience-centric strategy.

By combining Lundbeck’s deep domain expertise in brain disease with OpenAI’s advanced language- and data-processing models, both companies aim to explore new ways of generating insights, optimising workflows and ultimately improving the lives of people affected by neurological and psychiatric conditions.